including a diuretic., Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose
Conditions
Brief summary
Change from baseline in ambulatory 24‑hour average SBP at Week 12.
Detailed description
Change from baseline in ambulatory night-time average SBP at Week 12., Change from baseline in ambulatory daytime average SBP at Week 12., Change from baseline in seated SBP at Week 12., Participants achieving ambulatory 24-hour average SBP of < 130 mmHg at Week 12., Change from baseline in ambulatory 24-hour average DBP at Week 12., Change from baseline in ambulatory night-time average DBP at Week 12., Change from baseline in ambulatory daytime average DBP at Week 12., Change from baseline on seated DBP at Week 12., Participants achieving a nocturnal SBP dipping of ≥ 10% at Week 12
Interventions
DRUGBaxdrostat
Sponsors
Astrazeneca AB
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in ambulatory 24‑hour average SBP at Week 12. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in ambulatory night-time average SBP at Week 12., Change from baseline in ambulatory daytime average SBP at Week 12., Change from baseline in seated SBP at Week 12., Participants achieving ambulatory 24-hour average SBP of < 130 mmHg at Week 12., Change from baseline in ambulatory 24-hour average DBP at Week 12., Change from baseline in ambulatory night-time average DBP at Week 12., Change from baseline in ambulatory daytime average DBP at Week 12., Change from baseline on seated DBP at Week 12., Participants achieving a nocturnal SBP dipping of ≥ 10% at Week 12 | — |
Countries
Belgium, Bulgaria, Czechia, Germany, Greece, Hungary, Poland, Slovakia, Spain
Outcome results
None listed